Related Experiment Video

Updated: Jun 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Strategies in castration-resistant prostate cancer]

T Bessede1, P Beuzeboc, F Bladou

  • 1Service d'Urologie, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France. thomas.bessede@gmail.com

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|March 15, 2011
PubMed

Insights

Treating castration-resistant prostate cancer involves immediate or delayed strategies. Promising new therapies like endothelin inhibitors and novel anti-androgens are under investigation in clinical trials.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Context:

  • Castration-resistant prostate cancer (CRPC) presents complex treatment challenges.
  • Therapeutic decisions for CRPC depend on clinical circumstances and disease progression.
  • Advances in tumor biology are identifying novel therapeutic targets.

Purpose:

  • To review current and emerging treatment strategies for castration-resistant prostate cancer.
  • To highlight promising therapeutic agents and their developmental status.

Summary:

  • Treatment for CRPC can be initiated promptly or deferred based on patient factors.
  • Emerging treatments target specific tumor biology pathways.
  • Key investigational therapies include estrogens, novel anti-androgens (e.g., abiraterone, MDV3100, RD162), and endothelin inhibitors.

Impact:

  • This review provides an overview of the evolving landscape of CRPC treatment.
  • It emphasizes the importance of clinical trials for accessing novel therapeutic options.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...